Tecentriq Disappoints In Post-Surgery Bladder Cancer
Fails To Hit Disease-Free Survival
Executive Summary
Failure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.
You may also be interested in...
FDA Rejects Keytruda Dosing, Fast Tracks Tecentriq Lung Cancer Review
Keytruda is set to remain dominant despite knockback, though Tecentriq could claim prized NSCLC adjuvant approval first
Roche Has Blockbusters In Its Pipeline – But Demurs On Predicting Hits
Biosimilars will take a bigger bite out of revenues in 2020 but Roche should score some hits from its broad pipeline.
Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit
The company has pledged to continue developing its Duchenne in vivo gene editing therapy without Lilly, but will remain focused on its lead program in hepatitis B.